A375 pLNCX2
empty, A375 pLNCX2-PIK3CA
wt, and A375 pLNCX2-PIK3CA
H1047R were seeded in
60 mm cell culture dishes (Thermo Fisher Scientific, Waltham, MA, USA) at a density of 3 × 10
5 cells. After 24 h, each infected cell line was treated with increasing concentrations of the selected drugs: dabrafenib (0.0–0.5–2.0 nM), BYL719 (0.0–0.25–1.0 μM), and trametinib (0.0–0.5–1.0 nM). Combined treatments were obtained as follows: trametinib (0.0–0.25–0.5 nM) and dabrafenib (1.0 nM) for each trametinib dilution; BYL719 (0.0–0.25–1.0 μM) and dabrafenib (1.0 nM); and BYL719 (0.0–0.25–1.0 μM) and trametinib (0.5 nM). DMSO was used as control. All cell lines were treated for 48 h in standard culture conditions.
For each treatment, adherent cells were collected by scraping. Cell pellets were collected by centrifugation and stored at −80 °C. All experiments were conducted in triplicate.
Fixed doses of dabrafenib or trametinib in combined treatments (BYL719/Dabrafenib and BYL719/Trametinib, respectively) were used to evaluate the inhibitory responsiveness of MAPK pathway under gradual modulation of Akt signalling through different doses of BYL719. Similarly, increasing doses of trametinib were adopted in Trametinib/Dabrafenib treatment to investigate the effect of downstream inhibition of MAPK signalling on the cellular response to dabrafenib.
Candido S., Salemi R., Piccinin S., Falzone L, & Libra M. (2022). The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways. Pharmaceutics, 14(3), 590.